TB22 is a non-nucleoside inhibitor of DOT1LR231Q with anticancer activity. It inhibits the malignant phenotype of lung cancer cells harboring the R231Q mutation via the MAPK/ERK signaling pathway, making it useful for lung cancer research.
Target:
Histone Methyltransferase
* VAT and and shipping costs not included. Errors and price changes excepted
